NewsFeed
Headlines ASRM ESHRE FIGO ACOG Fertility and Sterility PCOS
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss – Reproduction and Fertility
Reproduction and Fertility/LinkedIn
Dec 13, 2025, 04:22

Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss – Reproduction and Fertility

Reproduction and Fertility shared a post on LinkedIn:

“Day 4 of RaFJC – Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss (RPL)

Recurrent pregnancy loss (RPL) (two or more consecutive miscarriages) affects 1–2% of couples worldwide. Up to 50% of cases remain unexplained, with immune maladaptation at the maternal–fetal interface increasingly recognised as a key driver.

Current therapies rely on systemic immunosuppression (corticosteroids, IVIG, TNF inhibitors), which:

  • Show inconsistent efficacy
  • Carry significant risks
  • Are costly and not always accessible

This highlights the urgent need for localised, safer, and cost‑effective therapies.

Mohsen Dashti, Vinnie A., and Mehdi Yousefi propose a placenta‑targeted nanoparticle (NP) system for localized immune cloaking.

Core design:

  • PLGA biodegradable matrix
  • Lipid‑PEG stealth layer to prolong circulation
  • SPIONs for imaging and tracking
  • Placental‑homing peptides for site‑specific delivery

Evidence so far:

  • Rodent and primate models show placenta‑specific NP delivery is feasible
  • NPs can induce anti‑inflammatory cytokines, suppress cytotoxic NK/T cells, and remodel spiral arteries
  • Ex vivo human placenta models confirm uptake with minimal fetal exposure

Estimated cost: $0.56–$5.58 per dose, far cheaper than IVIG or biologics. Production is scalable.

In conclusion, placenta‑targeted nanoparticles represent a promising therapy for unexplained RPL, offering localized immune tolerance while avoiding systemic risks.

Read the full article.

Join the discussion in the comments:

  • What challenges must be overcome for clinical translation?
  • How might localised immune cloaking reshape patient care?
  • Which biomarkers should guide future trials?

Explore the Special Collection: Immune Regulation and Inflammatory Mechanisms in Reproductive Health and Disease.”

Recurrent Pregnancy Loss

Stay updated on all scientific advances in the field of fertility with Fertility News.

Fertility Fertility News Mehdi Yousefi Mohsen Dashti Placenta-Targeted Nanoparticles PLGA Recurrent Pregnancy Loss Reproduction and Fertility reproductive health Vinnie A.
NewsFeed